Progress in new diagnosis and therapeutic strategy for gastrointestinal malignancy: focus on new molecular-targeted

Toshiro Sugiyama1

  • 1Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Digestion
|January 31, 2015
PubMed

Insights

This review summarizes advancements in diagnosing and treating gastrointestinal cancers, focusing on molecular-targeted therapies for gastrointestinal stromal tumors (GIST) and neuroendocrine tumors (NET). It highlights key findings from Japanese Gastroenterological Association meetings and revised GIST guidelines.

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Japanese Gastroenterological Association (JGA) annual meetings consistently address gastrointestinal malignancy diagnostics and therapeutics.
  • Recent focus includes molecular-targeted treatments for gastrointestinal stromal tumors (GIST), neuroendocrine tumors (NET), and GI cancers.

Purpose of the Study:

  • To review progress in diagnostics and therapy for gastrointestinal cancers presented at JGA meetings (2012-2014).
  • To summarize the recently revised Japanese guidelines for GIST diagnosis and management.
  • To discuss novel concepts and therapeutic strategies for GI cancers, NET, and GIST.

Main Methods:

  • Review of presentations from JGA annual scientific meetings (2012-2014).
  • Analysis of the World Health Organization's 2010 classification of NET.
  • Examination of published management guidelines for GIST (NCCN, ESMO, Japan) and the revised Japanese guidelines.

Main Results:

  • JGA meetings showcased advancements in diagnostics and molecular-targeted therapies for GIST, colorectal carcinomas, and GI lymphoma.
  • The WHO reclassified NET in 2010, removing the term 'carcinoid'.
  • Revised Japanese guidelines for GIST diagnosis and management are available.

Conclusions:

  • Continuous progress in molecular-targeted treatments is evident for various GI cancers.
  • Updated guidelines are crucial for optimal management of GIST.
  • The review provides insights into recent developments in gastroenterological oncology.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1000